Cargando…

Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer

PURPOSE: The purpose of this study is to report the long-term outcomes and toxicity results of a prospective trial of moderately hypofractionated, image guided radiation therapy (RT) for localized prostate cancer. METHODS AND MATERIALS: Patients were enrolled between December 2006 and February 2012....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wei Gang, Yan, Di, Ye, Hong, Gustafson, Gary, Ghilezan, Michael, Martinez, Alvaro, Krauss, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000067/
https://www.ncbi.nlm.nih.gov/pubmed/29904741
http://dx.doi.org/10.1016/j.adro.2017.12.006
_version_ 1783331607130669056
author Wang, Wei Gang
Yan, Di
Ye, Hong
Gustafson, Gary
Ghilezan, Michael
Martinez, Alvaro
Krauss, Daniel
author_facet Wang, Wei Gang
Yan, Di
Ye, Hong
Gustafson, Gary
Ghilezan, Michael
Martinez, Alvaro
Krauss, Daniel
author_sort Wang, Wei Gang
collection PubMed
description PURPOSE: The purpose of this study is to report the long-term outcomes and toxicity results of a prospective trial of moderately hypofractionated, image guided radiation therapy (RT) for localized prostate cancer. METHODS AND MATERIALS: Patients were enrolled between December 2006 and February 2012. Patients in group 1 were stage T1-T2b, had a Gleason score (GS) of 2 to 6 or 7 (3 + 4) with only 1 lobe involved, and had prostate-specific antigen levels ≤10 ng/mL. Group 2 patients were stage ≥T2c, had a GS ≥7 (4 + 3), a GS 7 (3 + 4) involving both lobes, or a PSA >10 ng/mL and ≤30 ng/mL. All patients underwent transrectal ultrasound guided fiducial (Visicoil) placement prior to computed tomography/magnetic resonance imaging simulation. Daily cone beam computed tomography with online correction was used. The prescribed dose was 64 Gy in 20 fractions. The primary endpoint was acute and late toxicity. The secondary endpoint was biochemical control. RESULTS: A total of 40 patients with a median age of 70 years were recruited for the study. Twenty-two patients (55%) were in group 1, and 18 patients (45%) were in group 2. Thirteen patients (32.5%) were classified as low, 26 patients (65%) as intermediate, and 1 patient (2.5%) as high risk per the National Comprehensive Cancer Network criteria. The median follow-up time was 59 months. Five-year biochemical control was 100% and 94.4% for groups 1 and 2, respectively. Thirteen patients (32.5%) developed acute gastrointestinal (GI) toxicities grade ≥2 and 3 (7.5%) developed acute grade 3 GI toxicity. A total of 17 patients (42.5%) developed grade ≥2 acute genitourinary toxicities and 1 (2.5%) developed acute grade 3 dysuria. Two patients (5%) developed late GI toxicities grade ≥2. There was 1 case (2.5%) of grade 4 fistula requiring sigmoid resection. Seven patients (17.5%) developed grade ≥2 late genitourinary toxicities; 2 patients (5%) late grade 3 urinary frequency/urgency. CONCLUSIONS: Moderately hypofractionated RT is effective with favorable toxicity and biochemical control, providing further evidence that increasing daily fractional dose can be safely and effectively delivered with contemporary RT techniques.
format Online
Article
Text
id pubmed-6000067
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-60000672018-06-14 Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer Wang, Wei Gang Yan, Di Ye, Hong Gustafson, Gary Ghilezan, Michael Martinez, Alvaro Krauss, Daniel Adv Radiat Oncol Prostate Cancer PURPOSE: The purpose of this study is to report the long-term outcomes and toxicity results of a prospective trial of moderately hypofractionated, image guided radiation therapy (RT) for localized prostate cancer. METHODS AND MATERIALS: Patients were enrolled between December 2006 and February 2012. Patients in group 1 were stage T1-T2b, had a Gleason score (GS) of 2 to 6 or 7 (3 + 4) with only 1 lobe involved, and had prostate-specific antigen levels ≤10 ng/mL. Group 2 patients were stage ≥T2c, had a GS ≥7 (4 + 3), a GS 7 (3 + 4) involving both lobes, or a PSA >10 ng/mL and ≤30 ng/mL. All patients underwent transrectal ultrasound guided fiducial (Visicoil) placement prior to computed tomography/magnetic resonance imaging simulation. Daily cone beam computed tomography with online correction was used. The prescribed dose was 64 Gy in 20 fractions. The primary endpoint was acute and late toxicity. The secondary endpoint was biochemical control. RESULTS: A total of 40 patients with a median age of 70 years were recruited for the study. Twenty-two patients (55%) were in group 1, and 18 patients (45%) were in group 2. Thirteen patients (32.5%) were classified as low, 26 patients (65%) as intermediate, and 1 patient (2.5%) as high risk per the National Comprehensive Cancer Network criteria. The median follow-up time was 59 months. Five-year biochemical control was 100% and 94.4% for groups 1 and 2, respectively. Thirteen patients (32.5%) developed acute gastrointestinal (GI) toxicities grade ≥2 and 3 (7.5%) developed acute grade 3 GI toxicity. A total of 17 patients (42.5%) developed grade ≥2 acute genitourinary toxicities and 1 (2.5%) developed acute grade 3 dysuria. Two patients (5%) developed late GI toxicities grade ≥2. There was 1 case (2.5%) of grade 4 fistula requiring sigmoid resection. Seven patients (17.5%) developed grade ≥2 late genitourinary toxicities; 2 patients (5%) late grade 3 urinary frequency/urgency. CONCLUSIONS: Moderately hypofractionated RT is effective with favorable toxicity and biochemical control, providing further evidence that increasing daily fractional dose can be safely and effectively delivered with contemporary RT techniques. Elsevier 2017-12-29 /pmc/articles/PMC6000067/ /pubmed/29904741 http://dx.doi.org/10.1016/j.adro.2017.12.006 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Prostate Cancer
Wang, Wei Gang
Yan, Di
Ye, Hong
Gustafson, Gary
Ghilezan, Michael
Martinez, Alvaro
Krauss, Daniel
Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer
title Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer
title_full Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer
title_fullStr Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer
title_full_unstemmed Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer
title_short Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer
title_sort outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer
topic Prostate Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000067/
https://www.ncbi.nlm.nih.gov/pubmed/29904741
http://dx.doi.org/10.1016/j.adro.2017.12.006
work_keys_str_mv AT wangweigang outcomesandtoxicityfromaprospectivestudyofmoderatelyhypofractionatedradiationtherapyforprostatecancer
AT yandi outcomesandtoxicityfromaprospectivestudyofmoderatelyhypofractionatedradiationtherapyforprostatecancer
AT yehong outcomesandtoxicityfromaprospectivestudyofmoderatelyhypofractionatedradiationtherapyforprostatecancer
AT gustafsongary outcomesandtoxicityfromaprospectivestudyofmoderatelyhypofractionatedradiationtherapyforprostatecancer
AT ghilezanmichael outcomesandtoxicityfromaprospectivestudyofmoderatelyhypofractionatedradiationtherapyforprostatecancer
AT martinezalvaro outcomesandtoxicityfromaprospectivestudyofmoderatelyhypofractionatedradiationtherapyforprostatecancer
AT kraussdaniel outcomesandtoxicityfromaprospectivestudyofmoderatelyhypofractionatedradiationtherapyforprostatecancer